AU2022275939A1 - Method of treating alzheimer's disease - Google Patents

Method of treating alzheimer's disease Download PDF

Info

Publication number
AU2022275939A1
AU2022275939A1 AU2022275939A AU2022275939A AU2022275939A1 AU 2022275939 A1 AU2022275939 A1 AU 2022275939A1 AU 2022275939 A AU2022275939 A AU 2022275939A AU 2022275939 A AU2022275939 A AU 2022275939A AU 2022275939 A1 AU2022275939 A1 AU 2022275939A1
Authority
AU
Australia
Prior art keywords
treatment according
subject
administered
daily dose
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022275939A
Other languages
English (en)
Inventor
Sharon L. Rogers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amyriad Pharma Inc
Original Assignee
Amyriad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amyriad Pharma Inc filed Critical Amyriad Pharma Inc
Publication of AU2022275939A1 publication Critical patent/AU2022275939A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022275939A 2021-05-19 2022-05-19 Method of treating alzheimer's disease Pending AU2022275939A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163190299P 2021-05-19 2021-05-19
US63/190,299 2021-05-19
US202163192398P 2021-05-24 2021-05-24
US63/192,398 2021-05-24
US202263331011P 2022-04-14 2022-04-14
US63/331,011 2022-04-14
PCT/US2022/030020 WO2022246059A1 (en) 2021-05-19 2022-05-19 Method of treating alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2022275939A1 true AU2022275939A1 (en) 2023-11-16

Family

ID=84104208

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022275939A Pending AU2022275939A1 (en) 2021-05-19 2022-05-19 Method of treating alzheimer's disease

Country Status (8)

Country Link
US (3) US20220370443A1 (https=)
EP (1) EP4340834A4 (https=)
JP (1) JP2024518455A (https=)
KR (1) KR20240021760A (https=)
AU (1) AU2022275939A1 (https=)
CA (1) CA3217579A1 (https=)
MX (1) MX2023013537A (https=)
WO (1) WO2022246059A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60006145T2 (de) * 1999-07-30 2004-06-09 Zenyaku Kogyo K.K. Azaindolizinon-derivate und agenzien zur verbesserung der kognitiver fähigkeiten,die dieselben als aktive inhaltstoffe enthalten
JP2012512173A (ja) * 2008-12-15 2012-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アミロイド前駆体タンパク質の切断を誘導して新規断片を形成させる方法
CN102573839A (zh) * 2009-05-11 2012-07-11 加利福尼亚大学董事会 降低泛素化蛋白水平的方法
WO2012094612A1 (en) * 2011-01-07 2012-07-12 Zenyaku Kogyo Kabushikikaisha Method of treating essential tremor

Also Published As

Publication number Publication date
CA3217579A1 (en) 2022-11-24
WO2022246059A1 (en) 2022-11-24
EP4340834A1 (en) 2024-03-27
US20220370443A1 (en) 2022-11-24
JP2024518455A (ja) 2024-05-01
US20250375444A1 (en) 2025-12-11
EP4340834A4 (en) 2025-04-02
MX2023013537A (es) 2024-02-06
KR20240021760A (ko) 2024-02-19
US20240156812A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
Chapple et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial
Fabre et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo
Chase et al. Donepezil plus solifenacin (CPC-201) treatment for Alzheimer's disease
US20180117148A1 (en) Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
JP2026001038A (ja) 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤
US20110319384A1 (en) Pharmaceutical Compositions
US20190015399A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
JP2019526571A (ja) 認知症の処置
AU2019446955A1 (en) Novel pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders
JP2020510675A (ja) ミトコンドリア起源のｒｏｓの産生の特異的阻害剤を使用した、薬物誘発ｑｔ間隔延長に関連するリスクの予防
KR20230154967A (ko) 환각 및 치매 관련 정신병의 치료에서 메비달렌 및 다른 d1 양성 알로스테릭 조절제의 용도
US20220370454A1 (en) Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics
JP2022514659A (ja) ドーパミン作動性ｃｎｓ障害の治療におけるｌｙ３１５４２０７の使用のための用量レジメン
US20220370443A1 (en) Method of treating alzheimer's disease
CA3143790A1 (en) Therapeutic interactions of leucomethylthioninium
CN119730840A (zh) 用于治疗重度抑郁症的1-(萘-2-基)-3-氮杂双环[3.1.0]己烷
HK40103192A (zh) 治疗阿尔茨海默病的方法
CN117529318A (zh) 治疗阿尔茨海默病的方法
RU2845317C1 (ru) Способ лечения постковидного синдрома
EP4069232B1 (en) Masupirdine for treating behavioral and psychological symptoms in dementia
Capsules Pr APO-FINGOLIMOD
CA3219499A1 (en) Synergistic effects on weight loss, improved quality of life and gastro-intestinal side effects with a composition of orlistat and acarbose
WO2024211216A1 (en) Cilnidipine and a p-glycoprotein inhibitor for treating pain
HK40071665A (en) Treating behavioral and psychological symptoms in dementia patients
Patel Dhaval et al. PHARMA SCIENCE MONITOR